updated 5/17/2011 7:16:34 AM ET 2011-05-17T11:16:34

DALLAS, May 17, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Avanir Pharmaceuticals Inc. (Nasdaq:AVNR). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/AVNR

Avanir Pharmaceuticals Inc. (AVNR) is a pharmaceutical company focused on developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. In October 2010, the U.S. Food and Drug Administration (FDA) approved NUEDEXTA for the treatment of pseudobulbar affect (PBA). The company's first commercialized product, docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the FDA.

This newsletter has been helping traders make great investment decisions on AVNR; click here for a 25% discount offer.

In the report, the analyst notes:

"AVNR saw strength on Monday, with shares gaining almost 3% to close the session $3.97, ahead of a presentation at this year's meeting of the American Psychiatric Association (APA). About 16 million shares have traded hands during the session, versus the 10-day average volume of 7.92 million."

"The Company reported total net revenue of $1.4 million for the three months that ended March 31, compared with $1 million for the comparable quarter in 2010. AVNR posted a net loss of $14.5 million, or $0.12 a share, compared to a net loss of $6.4 million, or $0.08 a year ago. Analysts, on average, were expecting a loss of $0.15 a share on revenue of $2.4 million, according to a poll by FactSet."

To read the entire report visit: www.microstockprofit.com/lp/AVNR

See what investors are saying about AVNR at http://www.stockhideout.com

Get breaking news on AVNR at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Brian Johnson
         info@microstockprofit.com
         1-888-307-2850

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.97%
$30K home equity loan FICO 5.23%
$75K home equity loan FICO 4.67%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.28%
13.21%
Cash Back Cards 17.74%
17.70%
Rewards Cards 17.01%
16.96%
Source: Bankrate.com